Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q2 FY23 results · Jul–Sep 2022
Gufic Biosciences reported revenue from operations of ₹174.84 crore (down 9.9% from Q2 FY22) and net profit of ₹20.21 crore (down 13.4% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a standalone basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 174.84 | 194.14 | −9.9% | 165.28 | +5.8% |
| Other income | 0.82 | 0.30 | +168.3% | 0.37 | +118.4% |
| Total income | 175.65 | 194.44 | −9.7% | 165.65 | +6.0% |
| Profit before tax | 27.26 | 30.39 | −10.3% | 28.28 | −3.6% |
| Net profit for the period | 20.21 | 23.34 | −13.4% | 21.05 | −4.0% |
| EPS, basic (₹) | 2.09 | 2.41 | −13.2% | 2.17 | −3.7% |
| Net margin (%) | 11.6 | 12.0 | 12.7 |
Standalone
- Filed with BSE
- 23 Nov 2022, 17:37 IST
- Board meeting
- 11 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE